Geron Corporation (GERN) Covered Calls

Geron Corporation covered calls Geron Corporation is developing biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes.

You can sell covered calls on Geron Corporation to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for GERN (prices last updated Fri 4:16 PM ET):

Geron Corporation (GERN) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
4.07 +0.05 4.05 4.11 6.8M - 2.4
Covered Calls For Geron Corporation (GERN)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Dec 20 4 0.25 3.86 3.6% 45.3%
Jan 17 4 0.35 3.76 6.4% 41.0%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Geron Corp. discovers and develops therapeutic products for cancer. It is a clinical stage biopharmaceutical company developing a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company's imetelstat, their sole product candidate, is a potent and specific inhibitor of telomerase. Based on clinical data, they may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or MF, which includes patients with primary MF, post-essential thrombocythemia MF, myelodysplastic syndromes, acute myelogenous leukemia. Geron was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.